Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Tuesday

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, analysts expect Jasper Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Jasper Therapeutics Stock Up 2.0 %

JSPR traded up $0.09 during mid-day trading on Friday, reaching $4.52. 129,296 shares of the company traded hands, compared to its average volume of 290,779. The stock has a market capitalization of $67.90 million, a P/E ratio of -0.95 and a beta of 2.74. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.84. The company's fifty day moving average price is $4.66 and its 200-day moving average price is $11.43.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JSPR shares. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.